Results 201 to 210 of about 61,970 (240)
Some of the next articles are maybe not open access.
Multidrug‐Resistant Tuberculosis
Annals of the New York Academy of Sciences, 2001Abstract: The costs of multidrug‐resistant tuberculosis (MDR TB) reach far beyond the cost of the clinical treatment of the patient. The first impact of the discovery of MDR TB in a population is the need to recognize that all TB patients have the potential of being MDR.
openaire +2 more sources
Multidrug-Resistant Tuberculosis Spondylitis
Acta Clinica Belgica, 2000We report a case of multidrug-resistant spinal tuberculosis complicated by epiduritis and paraspinal abscess in a 68-year-old black woman. Multidrug-resistant tuberculous spondylitis is still rare in Belgium. Two others cases were reported from 1992 to 1997.
Cherifi, Soraya +2 more
openaire +3 more sources
Linezolid for multidrug-resistant tuberculosis
The Lancet Infectious Diseases, 2013In their Comment in The Lancet Infectious Diseases, Kwok-Chiu Chang and colleagues concluded that expansion of access to linezolid for complicated cases of drug-resistant tuberculosis risks the loss of a potentially useful drug and could promote the emergence and spread of drug-resistant tuberculosis in the community.
Helen, Cox +3 more
openaire +2 more sources
Management of Multidrug-Resistant Tuberculosis
Chemotherapy, 1999Drug-resistant tuberculosis (TB) originally is the product of inadequate therapy; this may entail noncompliance with treatment, interrupted drug supplies, or inappropriate prescription. Patients may sequentially acquire resistance to several drugs through repetition of this process.
openaire +2 more sources
The challenge of multidrug resistant tuberculosis
Hospital Medicine, 2001Multidrug resistant tuberculosis (MDRTB) is defined as resistance to the two principal drugs used to treat TB, isoniazid and rifampicin, whether there is resistance to other drugs or not. It is a relatively new phenomenon and poses one of the most difficult therapeutic problems in medicine because failure may not only mean death of the patient but ...
openaire +2 more sources
Treatment and Prevention of Multidrug-Resistant Tuberculosis
Drugs, 1999Multidrug-resistant tuberculosis (MDRTB), which is defined as combined resistance to isoniazid and rifampicin, is a 'man-made' disease that is caused by improper treatment, inadequate drug supplies or poor patient supervision. Patients with MDRTB face chronic disability and death, and represent an infectious hazard for the community.
Bastian, I., Colebunders, R.
openaire +3 more sources
▼Bedaquiline for multidrug-resistant tuberculosis
Drug and Therapeutics Bulletin, 2014Resistance to drugs used to treat tuberculosis (TB) is a major public health problem that threatens progress made in TB management and control worldwide.1 It may result from improper use of antibiotics, including prescription of non-standard treatment regimens and poor adherence to drug therapy.
openaire +2 more sources
Quinolones and Multidrug-Resistant Tuberculosis
Chemotherapy, 1999The prevalence of initial resistance of multidrug-resistant tuberculosis (MDR-TB) to at least isoniazid (INH) and rifampicin (RFP) in Thailand during the period 1993–1997 is reported; in this era, trends for INH + RFP + streptomycin (SM) and ethambutol (EMB), INH + RFP + SM or EMB and MDR-TB were stable. The prevalence of acquired MDR-TB is on a slight
openaire +2 more sources
Testicular tuberculosis in multidrug-resistant pulmonary tuberculosis
Journal of Infection and Chemotherapy, 2013We report a rare case of multidrug-resistant pulmonary and testicular tuberculosis (TB) in a 25-year-old immunocompetent patient. The patient was suspected to have a testicular cancer. He underwent radical orchiectomy, and surgical pathology revealed a granuloma containing acid-fast bacilli in the testis.
Joo Wan, Seo +8 more
openaire +2 more sources
Treatment of multidrug-resistant tuberculosis
Journal of Hospital Infection, 1995Recent outbreaks of multi-drug-resistant tuberculosis (MDR-TB) have resulted in significant morbidity and mortality in patients with AIDS. The poor outcomes are attributable to delayed diagnoses, slow reporting of antimycobacterial susceptibility results, inadequate treatment regimens and profound immunosuppression.
openaire +2 more sources